InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a note issued to investors on Friday. The brokerage set a "sell" rating on the stock.

Separately, Piper Sandler restated an "overweight" rating and issued a $4.50 price objective on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Trading Up 0.8 %

Shares of InspireMD stock traded up $0.02 during trading hours on Friday, reaching $2.48. The stock had a trading volume of 11,502 shares, compared to its average volume of 23,821. The firm has a 50 day simple moving average of $2.69 and a two-hundred day simple moving average of $2.55. The firm has a market capitalization of $61.83 million, a price-to-earnings ratio of -3.35 and a beta of 0.91. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.77.

InspireMD (NYSE:NSPR - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). The firm had revenue of $1.74 million during the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter last year, the business earned ($0.24) earnings per share. Sell-side analysts forecast that InspireMD will post -0.82 EPS for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. boosted its holdings in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) by 266.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,513,641 shares of the company's stock after purchasing an additional 1,827,579 shares during the quarter. InspireMD makes up approximately 4.6% of Rosalind Advisors Inc.'s holdings, making the stock its 8th largest holding. Rosalind Advisors Inc. owned about 10.08% of InspireMD worth $6,272,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.78% of the company's stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.